X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (52) 52
gastroenterology & hepatology (50) 50
index medicus (44) 44
male (30) 30
female (28) 28
middle aged (24) 24
adult (19) 19
hepatitis c (19) 19
cirrhosis (14) 14
treatment outcome (14) 14
hepatitis c, chronic - drug therapy (13) 13
spain (13) 13
risk factors (12) 12
aged (11) 11
antiviral agents - therapeutic use (11) 11
gastroenterology and hepatology (10) 10
hepatitis c, chronic - virology (10) 10
fibrosis (9) 9
retrospective studies (9) 9
virus-infection (9) 9
genotype (8) 8
hepacivirus - genetics (8) 8
liver (8) 8
liver cirrhosis - physiopathology (8) 8
liver diseases (8) 8
ribavirin (8) 8
antiviral agents - administration & dosage (7) 7
chronic hepatitis c (7) 7
disease progression (7) 7
drug therapy, combination (7) 7
hepatitis (7) 7
hepatocellular-carcinoma (7) 7
infection (7) 7
interferon (7) 7
patients (7) 7
safety (7) 7
sustained virological response (7) 7
aged, 80 and over (6) 6
biomarkers - blood (6) 6
cohort studies (6) 6
digestive system diseases (6) 6
disease (6) 6
hcv (6) 6
medicine, general & internal (6) 6
oncology (6) 6
prevalence (6) 6
ribavirin - administration & dosage (6) 6
sofosbuvir (6) 6
steatosis (6) 6
viral load (6) 6
animals (5) 5
association (5) 5
chronic infection (5) 5
hepatitis b surface antigens - blood (5) 5
hepatitis c antibodies - blood (5) 5
hepatocellular carcinoma (5) 5
infectious diseases (5) 5
interferon-alpha - therapeutic use (5) 5
liver - virology (5) 5
liver cirrhosis - blood (5) 5
nafld (5) 5
polyethylene glycols - therapeutic use (5) 5
ribavirin - therapeutic use (5) 5
severity of illness index (5) 5
sustained virologic response (5) 5
virus activation (5) 5
antiviral agents (4) 4
ascites (4) 4
care and treatment (4) 4
combination therapy (4) 4
diagnosis (4) 4
dna, viral - blood (4) 4
epidemiology (4) 4
genotypes (4) 4
glomerular filtration rate (4) 4
hbv infection (4) 4
hepatitis b - virology (4) 4
hepatitis b virus (4) 4
hepatitis b virus - genetics (4) 4
hepatitis b virus - growth & development (4) 4
hepatitis b virus - immunology (4) 4
hepatitis b virus - pathogenicity (4) 4
hepatitis c virus (4) 4
hepatitis c, chronic - complications (4) 4
hepatitis c, chronic - physiopathology (4) 4
hepatology (4) 4
liver - pathology (4) 4
liver cancer (4) 4
liver cirrhosis (4) 4
liver cirrhosis - complications (4) 4
liver cirrhosis - virology (4) 4
liver disease (4) 4
pegylated interferon (4) 4
predictive value of tests (4) 4
recombinant proteins (4) 4
spain - epidemiology (4) 4
surface-antigen (4) 4
topic highlight (4) 4
treatment-experienced patients (4) 4
virus replication (4) 4
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


PLoS ONE, ISSN 1932-6203, 09/2012, Volume 7, Issue 9, p. e45285
A role for the NADPH oxidases NOX1 and NOX2 in liver fibrosis has been proposed, but the implication of NOX4 is poorly understood yet. The aim of this work was... 
GROWTH-FACTOR-BETA | OXIDATIVE STRESS | TGF-BETA | INDUCED APOPTOSIS | ADENINE-DINUCLEOTIDE PHOSPHATE | MULTIDISCIPLINARY SCIENCES | FIBROGENESIS | DIFFERENTIATION | MESENCHYMAL TRANSITION | UP-REGULATION | Liver - virology | Hepatitis C, Chronic - pathology | Liver - enzymology | Gene Expression - drug effects | Apoptosis - drug effects | ATP Binding Cassette Transporter, Sub-Family B - deficiency | Carbon Tetrachloride | Humans | NADPH Oxidases - metabolism | Hepatitis C, Chronic - virology | Myofibroblasts - enzymology | Liver Cirrhosis - enzymology | Liver Cirrhosis - chemically induced | Liver - drug effects | Cell Transdifferentiation - drug effects | Hepatitis C, Chronic - enzymology | STAT3 Transcription Factor - deficiency | NADPH Oxidases - genetics | Hepacivirus - physiology | Hepatic Stellate Cells - virology | Myofibroblasts - virology | Hepatocytes - drug effects | STAT3 Transcription Factor - genetics | Hepatic Stellate Cells - drug effects | Cyclin-Dependent Kinase Inhibitor p16 - deficiency | Hepatic Stellate Cells - enzymology | Cyclin-Dependent Kinase Inhibitor p16 - genetics | NADPH Oxidase 4 | Myofibroblasts - drug effects | Mice, Knockout | Transforming Growth Factor beta - pharmacology | Animals | Liver Cirrhosis - virology | Signal Transduction - drug effects | Biopsy | Hepatocytes - virology | Liver Cirrhosis - pathology | Mice | ATP Binding Cassette Transporter, Sub-Family B - genetics | Hepatocytes - enzymology | Oxidases | Care and treatment | Liver diseases | Research | Gene expression | Liver cells | Animal models | Biomedical research | Mesenchyme | Liver | Carbon tetrachloride | Viruses | Activation | Metastasis | Experiments | NAD(P)H oxidase | Hepatitis | Genotype & phenotype | Cell activation | NOX4 protein | Rodents | Hepatology | Gastroenterology | CYBB protein | Fibroblasts | Growth factors | Medical research | Stellate cells | Patients | Pulmonary fibrosis | Hepatocytes | Cell death | Fibrosis | Hepatitis C virus | Hepatitis C | Cancer | Apoptosis | Bile | Malalties del fetge | Cèl·lules hepàtiques
Journal Article
Journal Article
Journal Article
Journal of Cellular Physiology, ISSN 0021-9541, 04/2012, Volume 227, Issue 4, pp. 1319 - 1325
Sorafenib increases survival rate of patients with advanced hepatocellular carcinoma (HCC). The mechanism underlying this effect is not completely understood.... 
GROWTH-FACTOR-BETA | HEPATOCYTES | ACTIVATION | PHYSIOLOGY | LIVER | RESISTANCE | HEPATOMA-CELLS | FETAL | INDUCTION | MULTIKINASE INHIBITOR | RAF/MEK/ERK PATHWAY | CELL BIOLOGY | Niacinamide - analogs & derivatives | Apoptosis - drug effects | Humans | Autocrine Communication - drug effects | Phenylurea Compounds | Gene Knockdown Techniques | Benzenesulfonates - pharmacology | Carcinoma, Hepatocellular - drug therapy | Liver Neoplasms - physiopathology | Apoptosis Regulatory Proteins - genetics | Liver Neoplasms - pathology | Antineoplastic Agents - pharmacology | Proto-Oncogene Proteins - antagonists & inhibitors | Carcinoma, Hepatocellular - physiopathology | Autocrine Communication - physiology | Liver Neoplasms - drug therapy | Angiogenesis Inhibitors - pharmacology | Proto-Oncogene Proteins - genetics | Transforming Growth Factor beta - pharmacology | Tumor Necrosis Factor-alpha - pharmacology | Signal Transduction - drug effects | Apoptosis Regulatory Proteins - antagonists & inhibitors | Carcinoma, Hepatocellular - pathology | Proto-Oncogene Proteins - physiology | Cell Line, Tumor | Apoptosis Regulatory Proteins - physiology | Signal Transduction - physiology | Cell Proliferation - drug effects | Pyridines - pharmacology | Apoptosis - physiology | Liver cancer | Càncer de fetge | Mort cel·lular | Cell death | TGF-beta | cancer | PUMA | TNF | hepatocytes | Biological Sciences | Naturvetenskap | Natural Sciences | Medical and Health Sciences | Medicin och hälsovetenskap | Biologiska vetenskaper
Journal Article
Journal Article
Revista Espanola de Enfermedades Digestivas, ISSN 1130-0108, 12/2017, Volume 109, Issue 12, pp. 807 - 808
Public funding decisions must be guided by criteria of scientific evidence, cost-effectiveness and economic evaluation. As an increase in health-effectiveness... 
VIRUS-INFECTION | GASTROENTEROLOGY & HEPATOLOGY | DASABUVIR | SAFETY | PLUS | Health Care Costs | Hepatitis C, Chronic - drug therapy | Health Services Accessibility | Hepatitis C, Chronic - economics | Humans | Spain
Journal Article
Alimentary Pharmacology & Therapeutics, ISSN 0269-2813, 12/2018, Volume 48, Issue 11-12, pp. 1260 - 1270
Journal Article
Journal of Hepatology, ISSN 0168-8278, 2017, Volume 66, Issue 6, pp. 1138 - 1148
Graphical abstract 
Gastroenterology and Hepatology | Antiviral agents | Ombitasvir | Ritonavir | Ledipasvir | Real-world | Genotype 1 | Paritaprevir | Sustained virologic response | Hepatitis C, Chronic | Sofosbuvir | Dasabuvir | Randomized controlled trials | PLUS RIBAVIRIN | VIRUS-INFECTION | CHRONIC HEPATITIS-C | SUSTAINED VIROLOGICAL RESPONSE | ALL-CAUSE MORTALITY | Chronic | HEPATOCELLULAR-CARCINOMA | TREATMENT-EXPERIENCED PATIENTS | Hepatitis C | GASTROENTEROLOGY & HEPATOLOGY | Uridine Monophosphate - administration & dosage | Humans | Middle Aged | Hepatitis C, Chronic - physiopathology | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Male | Carbamates - administration & dosage | Neoplasm Recurrence, Local - etiology | Liver Neoplasms - etiology | Young Adult | Uracil - administration & dosage | Benzimidazoles - administration & dosage | Ribavirin - administration & dosage | Aged, 80 and over | Adult | Female | Fluorenes - administration & dosage | Carcinoma, Hepatocellular - etiology | Retrospective Studies | Drug Therapy, Combination | Glomerular Filtration Rate | Ritonavir - administration & dosage | Antiviral Agents - therapeutic use | Genotype | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Spain | Anilides - administration & dosage | Antiviral Agents - adverse effects | Uridine Monophosphate - analogs & derivatives | Aged | Macrocyclic Compounds - administration & dosage | Sustained Virologic Response | Sulfonamides - administration & dosage | Cohort Studies | Uracil - analogs & derivatives | Genetic aspects | Safety and security measures | Hepatitis C virus
Journal Article
Hepatology, ISSN 0270-9139, 06/2017, Volume 65, Issue 6, pp. 1810 - 1822
Direct‐acting antiviral agents (DAAs) are highly effective and well tolerated in patients with chronic hepatitis C virus infection, including those with... 
SUSTAINED VIROLOGICAL RESPONSE | ACTING ANTIVIRAL THERAPY | ALL-CAUSE MORTALITY | HEPATOCELLULAR-CARCINOMA | PEGYLATED INTERFERON | SIMEPREVIR PLUS SOFOSBUVIR | GENOTYPE 1 INFECTION | HCV | RIBAVIRIN | REDUCES RISK | GASTROENTEROLOGY & HEPATOLOGY | Multivariate Analysis | Predictive Value of Tests | Prognosis | Humans | Middle Aged | Hepatitis C, Chronic - physiopathology | Liver Cirrhosis - mortality | Hepacivirus - genetics | Male | Hepatitis C, Chronic - mortality | Cause of Death | Ribavirin - administration & dosage | Aged, 80 and over | Adult | End Stage Liver Disease - drug therapy | Female | Registries | Retrospective Studies | Hepacivirus - drug effects | Liver Function Tests | Severity of Illness Index | Liver Cirrhosis - drug therapy | Risk Assessment | Kaplan-Meier Estimate | Proportional Hazards Models | Logistic Models | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Disease Progression | End Stage Liver Disease - pathology | Spain | End Stage Liver Disease - mortality | Liver Cirrhosis - virology | Sofosbuvir - administration & dosage | Survival Analysis | Aged | Liver Cirrhosis - physiopathology | Cohort Studies | End Stage Liver Disease - virology | Cirrhosis | Antiviral agents | Hepatitis | Liver diseases | Chronic infection | Data processing | Interferon | Hepatitis C | Patients
Journal Article
Journal Article
Liver International, ISSN 1478-3223, 01/2015, Volume 35, Issue 1, pp. 90 - 100
Journal Article